Efficacy and Safety Assessment of a Subcutaneous Immunotherapy (Beltavac) With Polymerized Allergenic Extract From House Dust Mites in Patients With Allergic Rhinitis/Rhinoconjuntivitis
Latest Information Update: 24 Jul 2024
Price :
$35 *
At a glance
- Drugs Alternaria allergy immunotherapy (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis; Asthma
- Focus Registrational; Therapeutic Use
- Acronyms PROACAROS
- Sponsors Probelte Pharma
- 18 Jul 2024 Planned End Date changed from 1 Feb 2024 to 1 Jun 2026.
- 18 Jul 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Jun 2026.
- 11 Oct 2021 New trial record